Nifty
:
24052.05
Sensex
:
77054.94
-158.95 (-0.66%)
-561.46 (-0.72%)
Nifty
Sensex
:
:
24052.05
77054.94
-158.95 (-0.66%)
-561.46 (-0.72%)

Aurobindo Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 524804 | NSE: AUROPHARMA

NSE BSE
1552.80
14-Jul-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1551.4
  •  1572
  •  1545.9
  •  1549.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  525859
  •  820444905.8
  •  1636.8
  •  1016.1

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 89,344.68
  • 25.44
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 87,150.59
  • 0.26%
  • 2.35

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.82%
  • 0.58%
  • 5.74%
  • FII
  • DII
  • Others
  • 15.24%
  • 22.84%
  • 3.78%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.68
  • 5.07
  • 8.47

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.52
  • 4.30
  • 12.10

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.58
  • -8.16
  • 21.84

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.60
  • 19.32
  • 22.11

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.20
  • 1.89
  • 2.18

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.64
  • 9.32
  • 10.67

Earnings Forecasts:

(Updated: 11-07-2026)
Description
2026
2027
2028
2029
Adj EPS
71
0
20.28
61.98
P/E Ratio
21.87
-
76.57
25.05
Revenue
20.12
17.41
15.95
33519.1
EBITDA
38852.1
42894.4
46232.6
6849.16
Net Income
8053.12
9044.07
9991.2
3599.77
ROA
4303.45
4981.17
4794.82
7.12
P/B Ratio
-0.39
-0.25
-0.20
2.53
ROE
2.2
1.98
1.77
10.49
FCFF
11.3
11.77
11.56
2473.7
FCFF Yield
1690.36
3401.1
4262.79
2.81
Net Debt
1.92
3.86
4.84
-1504.54
BVPS
-4019.15
-6185.03
-7844.2
612.86

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
8,853.34
8,382.12
5.62%
8,645.90
7,978.52
8.36%
8,285.70
7,796.07
6.28%
7,868.14
7,567.02
3.98%
Expenses
7,100.56
6,590.20
7.74%
6,872.56
6,400.54
7.37%
6,607.60
6,229.93
6.06%
6,265.11
5,947.45
5.34%
EBITDA
1,752.78
1,791.92
-2.18%
1,773.34
1,577.98
12.38%
1,678.10
1,566.14
7.15%
1,603.03
1,619.57
-1.02%
EBIDTM
19.80%
21.38%
20.51%
19.78%
20.25%
20.09%
20.37%
21.40%
Other Income
117.04
134.81
-13.18%
187.64
157.29
19.30%
120.59
136.00
-11.33%
105.30
220.93
-52.34%
Interest
98.21
115.02
-14.61%
92.77
118.48
-21.70%
95.24
112.70
-15.49%
97.75
111.04
-11.97%
Depreciation
478.57
444.43
7.68%
464.73
418.53
11.04%
429.19
382.28
12.27%
405.70
404.18
0.38%
PBT
1,293.04
1,367.28
-5.43%
1,338.15
1,198.26
11.67%
1,274.26
1,207.16
5.56%
1,204.88
1,325.28
-9.08%
Tax
369.77
432.26
-14.46%
428.72
354.28
21.01%
427.79
390.51
9.55%
382.60
405.67
-5.69%
PAT
923.27
935.02
-1.26%
909.43
843.98
7.75%
846.47
816.65
3.65%
822.28
919.61
-10.58%
PATM
10.43%
11.15%
10.52%
10.58%
10.22%
10.48%
10.45%
12.15%
EPS
15.86
15.56
1.93%
15.67
14.56
7.62%
14.61
14.07
3.84%
14.20
15.69
-9.50%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
33,653.08
31,723.73
29,001.87
24,855.38
23,455.49
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
Net Sales Growth
6.08%
9.39%
16.68%
5.97%
-5.32%
7.26%
18.07%
18.83%
10.42%
8.08%
 
Cost Of Goods Sold
13,488.36
11,671.89
11,348.78
10,190.48
9,238.91
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
Gross Profit
20,164.72
20,051.84
17,653.09
14,664.90
14,216.58
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
GP Margin
59.92%
63.21%
60.87%
59.00%
60.61%
64.37%
62.25%
59.69%
63.04%
60.35%
59.32%
Total Expenditure
26,845.83
25,140.94
23,158.87
21,136.74
19,070.95
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
Power & Fuel Cost
-
1,012.25
826.03
842.63
626.86
589.28
587.68
556.79
470.95
437.14
419.26
% Of Sales
-
3.19%
2.85%
3.39%
2.67%
2.38%
2.54%
2.85%
2.86%
2.93%
3.04%
Employee Cost
-
4,475.62
3,922.94
3,522.25
3,450.92
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
% Of Sales
-
14.11%
13.53%
14.17%
14.71%
14.27%
13.94%
13.21%
12.94%
11.86%
11.18%
Manufacturing Exp.
-
3,556.25
3,191.71
2,810.03
2,502.98
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
% Of Sales
-
11.21%
11.01%
11.31%
10.67%
11.61%
10.09%
10.42%
9.79%
8.78%
9.11%
General & Admin Exp.
-
1,551.60
1,483.77
1,386.66
1,335.03
1,473.59
1,320.69
1,006.68
1,068.22
997.32
686.38
% Of Sales
-
4.89%
5.12%
5.58%
5.69%
5.95%
5.72%
5.15%
6.49%
6.69%
4.98%
Selling & Distn. Exp.
-
2,185.06
1,684.72
1,685.76
1,496.67
1,564.17
1,524.75
1,125.76
1,025.85
848.43
877.14
% Of Sales
-
6.89%
5.81%
6.78%
6.38%
6.31%
6.60%
5.75%
6.23%
5.69%
6.36%
Miscellaneous Exp.
-
688.27
700.92
698.93
419.58
576.06
529.75
413.24
298.75
203.97
877.14
% Of Sales
-
2.17%
2.42%
2.81%
1.79%
2.33%
2.29%
2.11%
1.81%
1.37%
1.54%
EBITDA
6,807.25
6,582.79
5,843.00
3,718.64
4,384.54
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
EBITDA Margin
20.23%
20.75%
20.15%
14.96%
18.69%
21.53%
21.06%
20.20%
22.91%
23.03%
23.11%
Other Income
530.57
621.85
557.38
290.59
322.58
380.85
191.87
155.32
101.98
115.89
203.80
Interest
383.97
457.24
289.71
140.48
48.64
74.49
305.13
262.60
77.72
66.72
256.70
Depreciation
1,778.19
1,649.42
1,521.66
1,244.58
1,126.52
1,055.39
966.71
667.95
557.97
427.63
392.37
PBT
5,110.33
5,097.98
4,589.01
2,624.17
3,531.96
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
Tax
1,608.88
1,582.72
1,211.02
684.85
725.63
2,009.77
899.35
726.85
818.27
759.65
720.71
Tax Rate
31.48%
31.05%
27.54%
26.10%
21.32%
27.16%
23.93%
23.53%
25.27%
24.86%
26.28%
PAT
3,501.45
3,485.88
3,172.97
1,927.50
2,648.15
5,334.84
2,845.14
2,364.73
2,423.17
2,301.66
2,025.09
PAT before Minority Interest
3,503.23
3,483.57
3,168.97
1,927.65
2,647.11
5,333.82
2,843.69
2,364.50
2,422.91
2,301.19
2,023.59
Minority Interest
1.78
2.31
4.00
-0.15
1.04
1.02
1.45
0.23
0.26
0.47
1.50
PAT Margin
10.40%
10.99%
10.94%
7.75%
11.29%
21.53%
12.32%
12.09%
14.72%
15.44%
14.68%
PAT Growth
-0.39%
9.86%
64.62%
-27.21%
-50.36%
87.51%
20.32%
-2.41%
5.28%
13.66%
 
EPS
60.29
60.02
54.63
33.19
45.59
91.85
48.99
40.72
41.72
39.63
34.87

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
32,653.32
29,842.80
26,839.85
24,575.98
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
7,287.30
Share Capital
58.08
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.52
Total Reserves
32,595.24
29,784.21
26,781.26
24,517.39
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
7,227.50
Non-Current Liabilities
1,162.74
1,808.94
866.87
903.10
807.27
555.09
358.13
594.11
102.07
583.85
Secured Loans
1,159.38
2,134.90
618.96
249.21
168.49
0.00
48.88
26.96
177.59
380.10
Unsecured Loans
402.27
0.00
0.00
0.00
0.00
0.00
131.07
424.24
3.81
362.71
Long Term Provisions
282.93
225.70
172.72
171.79
157.11
74.71
46.54
55.86
39.13
23.36
Current Liabilities
14,682.34
12,199.13
11,493.78
8,155.98
10,665.05
11,384.64
12,020.57
8,665.89
6,605.60
7,840.22
Trade Payables
4,188.85
4,454.16
3,871.31
2,703.05
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
2,457.03
Other Current Liabilities
4,623.28
3,161.05
2,979.91
3,106.51
2,684.31
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
Short Term Borrowings
5,309.72
4,078.12
4,230.43
2,117.83
4,803.78
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
Short Term Provisions
560.49
505.80
412.13
228.59
382.28
511.72
384.67
294.23
261.36
132.93
Total Liabilities
48,492.01
43,858.87
39,212.50
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
Net Block
14,794.19
14,492.79
11,023.69
10,532.09
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
Gross Block
24,462.96
23,447.77
18,593.32
15,943.09
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
Accumulated Depreciation
9,659.15
8,952.24
7,569.63
5,411.00
4,239.75
3,044.79
2,022.77
1,374.10
801.71
390.14
Non Current Assets
21,329.55
19,653.24
17,666.83
15,510.44
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
5,419.57
Capital Work in Progress
4,899.96
3,868.72
5,390.01
3,747.20
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
848.14
Non Current Investment
251.70
321.65
391.74
618.30
431.22
554.69
360.20
311.52
245.85
122.94
Long Term Loans & Adv.
973.42
714.55
794.00
575.33
658.44
378.34
396.64
261.91
256.48
236.56
Other Non Current Assets
410.28
255.53
67.39
37.52
53.03
36.61
38.62
86.93
81.29
32.24
Current Assets
27,162.46
23,771.92
21,459.91
18,043.59
19,739.90
16,412.51
15,332.30
12,178.16
9,206.18
10,294.35
Current Investments
0.01
50.58
151.00
378.85
159.79
0.02
0.02
0.02
0.02
0.02
Inventories
10,543.72
9,808.23
8,511.23
7,553.85
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
Sundry Debtors
5,745.93
4,816.74
4,466.38
4,012.26
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
4,606.68
Cash & Bank
8,235.49
6,278.30
6,084.20
4,190.01
5,474.28
2,842.15
1,957.18
1,262.25
513.48
800.26
Other Current Assets
2,637.31
519.45
554.71
393.95
1,575.98
1,555.31
2,715.72
1,977.28
1,596.81
831.25
Short Term Loans & Adv.
1,983.31
2,298.62
1,692.39
1,514.67
1,058.30
1,065.96
795.90
753.96
512.09
366.88
Net Current Assets
12,480.12
11,572.79
9,966.13
9,887.61
9,074.85
5,027.87
3,311.73
3,512.27
2,600.58
2,454.13
Total Assets
48,492.01
43,425.16
39,126.74
33,554.03
33,317.70
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
3,924.62
2,434.52
2,386.75
5,016.48
3,329.05
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
PBT
5,066.29
4,379.99
2,612.50
3,372.74
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
Adjustment
1,834.16
1,496.24
1,586.47
1,344.13
-1,662.64
1,091.17
813.95
535.02
408.92
487.50
Changes in Working Capital
-1,244.48
-1,675.07
-1,094.98
1,557.80
-1,066.65
307.91
-1,484.50
-1,123.12
582.52
-1,079.41
Cash after chg. in Working capital
5,655.97
4,201.16
3,103.99
6,274.67
4,614.30
5,142.12
2,420.80
2,653.08
4,052.28
2,152.39
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,731.35
-1,766.64
-717.24
-1,258.19
-1,285.25
-760.84
-769.83
-698.56
-773.70
-732.63
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,875.80
-4,255.95
-3,977.75
-3,211.56
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
Net Fixed Assets
-141.97
2,277.63
-503.75
1,473.74
-428.03
-760.60
-799.00
-771.00
-1,092.24
125.11
Net Investments
-1,816.13
-5,288.07
-1,521.01
-1,574.43
-2,482.52
-188.35
-371.56
-285.55
-498.60
-170.60
Others
82.30
-1,245.51
-1,952.99
-3,110.87
3,509.24
-618.69
-1,732.03
-870.04
-196.20
-1,399.72
Cash from Financing Activity
119.78
800.42
1,814.41
-2,969.27
-1,364.94
-1,947.18
1,919.06
864.15
-1,915.26
365.44
Net Cash Inflow / Outflow
2,168.60
-1,021.01
223.41
-1,164.35
2,562.80
866.46
667.44
892.08
-423.72
339.99
Opening Cash & Equivalents
3,385.43
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
318.03
743.49
403.81
Closing Cash & Equivalent
5,563.79
3,385.43
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
319.63
743.50

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
562.21
509.35
458.10
419.46
374.29
287.16
237.08
199.36
159.96
124.50
ROA
7.54%
7.63%
5.29%
7.90%
17.34%
10.39%
10.00%
13.07%
14.44%
14.13%
ROE
11.15%
11.18%
7.50%
11.38%
27.81%
18.62%
18.47%
22.99%
27.57%
32.51%
ROCE
14.39%
13.76%
9.39%
12.71%
30.33%
18.79%
17.97%
22.72%
24.92%
27.35%
Fixed Asset Turnover
2.65
2.84
2.95
3.24
3.73
4.12
4.36
2.44
2.96
2.79
Receivable days
30.33
28.34
30.42
28.69
29.37
29.85
29.56
64.66
89.16
106.53
Inventory Days
58.44
55.92
57.65
63.29
62.82
57.72
59.64
112.70
101.43
100.27
Payable days
135.14
133.88
117.74
108.60
111.03
53.30
58.56
67.77
75.73
81.70
Cash Conversion Cycle
-46.37
-49.62
-29.67
-16.62
-18.84
34.27
30.63
109.58
114.86
125.10
Total Debt/Equity
0.24
0.21
0.18
0.10
0.23
0.33
0.50
0.41
0.36
0.69
Interest Cover
12.08
16.12
19.60
70.34
100.33
13.32
12.76
42.66
46.80
11.69

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Aurobindo Pharma’s arm incorporates subsidiary in Indonesia
    10th Jul 2026, 16:59 PM

    The object of incorporation of this wholly owned stepdown subsidiary is to undertake manufacturing operations in Indonesia

    Read More
  • Aurobindo Pharma’s arm completes acquisition of Lannett Company
    30th Jun 2026, 11:18 AM

    Lannett has become a wholly owned subsidiary of Aurobindo Pharma USA Inc

    Read More
  • USFDA completes inspection at Aurobindo Pharma’s arm’s Andhra Pradesh facility
    29th Jun 2026, 10:30 AM

    The inspection concluded with 2 observations and will be responded to within the stipulated time

    Read More
  • Aurobindo Pharma’s arm gets US FTC’s approval to acquire Lannett
    22nd Jun 2026, 09:08 AM

    The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to close before the end of June 2026

    Read More
  • USFDA completes PAI at Aurobindo Pharma’s arm’s Andhra Pradesh facility
    20th Jun 2026, 15:20 PM

    The inspection concluded with 5 observations

    Read More
  • Aurobindo Pharma’s arm gets US FTC’s nod for acquiring 100% of membership interest in Lannett
    19th Jun 2026, 12:59 PM

    This acquisition strengthens its ability to serve the U.S. generics space and provides strategic diversification into a specialized, high-value therapeutic category

    Read More
  • USFDA inspects Aurobindo Pharma’s arm’s Eugia Unit-III in Telangana
    13th Jun 2026, 14:41 PM

    The inspection had concluded with 11 observations

    Read More
  • Aurobindo Pharma gets USFDA’s final nod for Tofacitinib Tablets
    5th Jun 2026, 09:50 AM

    The product will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company and will be launched immediately

    Read More
  • Aurobindo Pharma inaugurates biologics contract manufacturing facility ‘TheraNym’
    4th Jun 2026, 12:11 PM

    The facility is intended to support MSD supply chain, both domestic and export markets, subject to applicable approvals and customer requirements

    Read More
  • Aurobindo Pharma’s arm’s Telangana facility classified as official action indicated
    25th May 2026, 14:11 PM

    The USFDA had conducted inspection of the said unit from February 16 to February 27, 2026

    Read More
  • Aurobindo Pharma reports marginal rise in Q4 consolidated net profit
    22nd May 2026, 16:58 PM

    Consolidated total income of the company increased by 5.32% at Rs 8,970.38 crore for Q4FY26

    Read More
  • Aurobindo Pharma’s arm incorporates wholly owned subsidiary in France
    22nd May 2026, 15:30 PM

    The object of incorporation of this wholly owned subsidiary is to expand the manufacturing of generic formulations in France

    Read More
  • Aurobindo Pharma’s arm gets CDSCO’s marketing authorisation for Bevqolva
    16th May 2026, 12:03 PM

    The authorisation permits manufacture at CuraTeQ’s facility in Hyderabad and marketing of Bevqolva in 100 mg/4mL and 400 mg/16 mL vial presentations

    Read More
  • Aurobindo Pharma gets EIR for Telangana unit
    6th May 2026, 11:00 AM

    The USFDA has classified the said facility as Voluntary Action Indicated

    Read More
  • Aurobindo Pharma’s arm gets Health Canada’s nod for Bevqolva bevacizumab biosimilar
    2nd May 2026, 10:41 AM

    Bevacizumab, a humanized monoclonal antibody, inhibits angiogenesis - the formation of new blood vessels - by blocking VEGF-A

    Read More
  • Aurobindo gets nod for Dextromethorphan Polistirex Extended-Release Oral Suspension
    18th Apr 2026, 14:16 PM

    The product will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary of the company, and will be launched in Q2FY27

    Read More
  • Aurobindo Pharma gets USFDA’s final nod for Glycerol Phenylbutyrate Oral Liquid
    17th Apr 2026, 11:12 AM

    The product will be manufactured by Unit-III of the company and will be launched immediately

    Read More
  • Aurobindo Pharma’s arm signs additional product schedule with MSD
    15th Apr 2026, 16:58 PM

    TheraNym will invest around $150 to $175 million for establishing said facility

    Read More
  • Aurobindo Pharma gets USFDA’s final nod for Dapagliflozin tablets
    8th Apr 2026, 14:11 PM

    These products will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary of the company

    Read More
  • Aurobindo Pharma gets final nod for Dapagliflozin, Metformin Hydrochloride Extended-Release Tablets
    8th Apr 2026, 09:50 AM

    These products will be manufactured at unit-IV of APL Healthcare, a wholly owned subsidiary of the Company and will be launched immediately

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.